Bichler A, Fuchs D, Hausen A, Hetzel H, Reibnegger G, Wachter H
Arch Gynecol. 1983;233(2):121-30. doi: 10.1007/BF02114788.
Urinary neopterin was measured in healthy women (n = 209) and men (n = 208), in patients with benign gynecological tumors (n = 53), in women with precancerous lesions of the cervix and the endometrium (n = 24) and in women with cancer of the genital tract (n = 108). In addition urinary neopterin measurements were made in 109 pregnant women and 20 women in the puerperium. No significant difference was found between mean neopterin values in patients with benign gynecological tumors, in women with precancerous lesions and in healthy women. Patients with cancer had significantly higher mean urinary neopterin levels than the control group. Raised neopterin levels were found in 56% of patients with genital tract cancer, the figures varying between 93% for ovarian cancer and 47% for cancer of the cervix. Some of the cancer patients had serial urinary neopterin measurements and in about 80% there was some relation between urinary neopterin values and clinical progress as judged clinically and radiologically, the best agreement existing in patients with ovarian cancer. Significantly higher mean neopterin values were found during normal pregnancy and in the early puerperium than in non-pregnant healthy controls. Raised urinary neopterin excretion may be due to enhanced cell proliferation and alloantigenic activation of T-lymphocytes.
对209名健康女性、208名健康男性、53名患有良性妇科肿瘤的患者、24名患有子宫颈和子宫内膜癌前病变的女性以及108名患有生殖道癌症的女性进行了尿新蝶呤检测。此外，还对109名孕妇和20名产褥期妇女进行了尿新蝶呤检测。结果发现，患有良性妇科肿瘤的患者、患有癌前病变的女性和健康女性的平均新蝶呤值之间没有显著差异。癌症患者的平均尿新蝶呤水平明显高于对照组。56%的生殖道癌症患者新蝶呤水平升高，其中卵巢癌患者的这一比例为93%，子宫颈癌患者为47%。一些癌症患者进行了系列尿新蝶呤检测，约80%的患者尿新蝶呤值与临床和放射学判断的临床进展之间存在某种关联，卵巢癌患者的一致性最佳。正常妊娠和产褥早期的平均新蝶呤值明显高于未怀孕的健康对照组。尿新蝶呤排泄增加可能是由于细胞增殖增强和T淋巴细胞的同种异体抗原激活所致。
